ADXS Ayala Pharmaceuticals Inc (CE)

On May 1, 2022, the Board of Directors of Advaxis, Inc. (the “Company”) elected Igor Gitelman, the Company’s VP of Finance and Chief Accounting Officer, to serve on an interim basis as the Company’s Chief Financial Officer in accordance with the Second Amended and Restated By-Laws of the Company, until his successor is chosen and qualified, or until his earlier resignation or removal. In this role, Mr. Gitelman will be the Company’s Principal Financial Officer. Kenneth A. Berlin, who had formerly served as interim Chief Financial Officer, remains the Company’s President and Chief Executive Officer.

Mr. Gitelman, age 46, has served as the Company’s VP of Finance since November 2020 and Chief Accounting Officer since February 2021. Before joining the Company, Mr. Gitelman served as CFO Executive Financial Consultant for Accu Reference Medical Labs, a clinical diagnostic laboratory. Before that, from February 2017 through November 2018, Mr. Gitelman served as a chief accounting officer of Cancer Genetics, Inc., a drug discovery, preclinical oncology, and immuno-oncology services company. Prior to that, Mr. Gitelman served as an Assistant to Vice President (AVP) of Finance and Tax at clinical diagnostic laboratory, BioReference Laboratories, Inc., from October 2005 to October 2016. During this time at BioReference Laboratories, Inc., Mr. Gitelman held various positions of increasing responsibility managing the company’s internal audit function, SEC financial reporting, tax and corporate finance functions.

There is no arrangement or understanding between Mr. Gitelman and any other persons pursuant to which Mr. Gitelman was appointed as interim Chief Financial Officer. There are no family relationships between Mr. Gitelman and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K, nor are any such transactions currently proposed.